Research Topics
| Mark A RitterSummaryAffiliation: University of Wisconsin Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Hypofractionation for prostate cancerMark Ritter
Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
Cancer J 15:1-6. 2009..With hypofractionation's significant potential for therapeutic gain, cost savings, and improved patient convenience, the future management of localized prostate cancer could be profoundly altered in the process...- Rationale, conduct, and outcome using hypofractionated radiotherapy in prostate cancerMark Ritter
Department of Human Oncology and Medical Physics, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
Semin Radiat Oncol 18:249-56. 2008..Clinical validation permitting, the adaptation of hypofractionation as a standard of care could profoundly influence future management of localized prostate cancer... - Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancerJarrod B Adkison
Department of Human Oncology, University of Wisconsin Carbone Cancer Center, School of Medicine and Public Health, Madison, WI 53792, USA
Int J Radiat Oncol Biol Phys 82:184-90. 2012..In a prospective trial, we tested whether image-guided intensity-modulated radiation therapy (IMRT) can safely deliver escalated nodal doses while treating the prostate with hypofractionated radiotherapy in 5½ weeks... - Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrenceTim J Kruser
Department of Human Oncology, University of Wisconsin Carbone Cancer Center, Madison, WI 53792, USA
Cancer 117:2629-36. 2011..5 to 8 weeks of treatment. The authors report on the safety and efficacy of an expedited radiotherapy course for salvage prostate radiotherapy... 
Pelvic nodal dose escalation with prostate hypofractionation using conformal avoidance defined (H-CAD) intensity modulated radiation therapyTheodore S Hong
Department of Human Oncology, University of Wisconsin Medical School, Madison, WI 53792, USA
Acta Oncol 45:717-27. 2006..A phase II trial to more thoroughly examine this treatment approach is currently underway...- Salvage hypofractionated radiotherapy for biochemically recurrent prostate cancer after radical prostatectomyGordon W Wong
Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
Int J Radiat Oncol Biol Phys 70:449-55. 2008..To evaluate whether hypofractionation is well tolerated and to preliminarily assess biochemical control of this regimen in a postprostatectomy, salvage setting... - A comprehensive assessment by tumor site of patient setup using daily MVCT imaging from more than 3,800 helical tomotherapy treatmentsLeah K Schubert
Department of Medical Physics, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA
Int J Radiat Oncol Biol Phys 73:1260-9. 2009..To assess patient setup corrections based on daily megavoltage CT (MVCT) imaging for four anatomic treatment sites treated on tomotherapy... - Integral radiation dose to normal structures with conformal external beam radiationHidefumi Aoyama
Department of Human Oncology, University of Wisconsin, Madison, WI, USA
Int J Radiat Oncol Biol Phys 64:962-7. 2006..This study was designed to evaluate the integral dose (ID) received by normal tissue from intensity-modulated radiotherapy (IMRT) for prostate cancer... - Megavoltage computed tomography: an emerging tool for image-guided radiotherapyTheodore S Hong
Department of Human Oncology, University of Wisconsin Medical School, Madison, WI, USA
Am J Clin Oncol 30:617-23. 2007..In this study, we assessed the image-quality, absorbed radiation doses, and clinical practicality of MVCT from our helical tomotherapy prototype unit... - The alpha/beta ratio for prostate cancer: what is it, really?Søren M Bentzen
Department of Human Oncology, University of Wisconsin Medical School, WI 53792, USA
Radiother Oncol 76:1-3. 2005..Taken together, the outcomes of these two studies still favor a high fractionation sensitivity of prostate cancer... - Helical tomotherapy: image guidance and adaptive dose guidanceWolfgang A Tome
Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
Front Radiat Ther Oncol 40:162-78. 2007.... - Helical tomotherapy: an innovative technology and approach to radiation therapyJames S Welsh
Department of Human Oncology, University of Wisconsin, School of Medicine, 600 Highland Avenue, Madison, WI 53792, USA
Technol Cancer Res Treat 1:311-6. 2002..Based on radiobiological principles that exploit the physical advantages of helical tomotherapy, several dosimetric and clinical investigations are underway... - Optimal stochastic correction strategies for rigid-body target motionHarry Keller
Department of Medical Physics, University of Wisconsin, Madison, WI 53706, USA
Int J Radiat Oncol Biol Phys 55:261-70. 2003..To derive optimal correction strategies for setup errors, including the uncertainty in their measurement, and to analyze their impact on treatment margins... - The role of p53 in radiation therapy outcomes for favorable-to-intermediate-risk prostate cancerMark A Ritter
Department of Human Oncology, University of Wisconsin, 600 Highland Avenue, Madison, WI 53792, USA
Int J Radiat Oncol Biol Phys 53:574-80. 2002.... - Effect of medical castration on CYP3A4 enzyme activity using the erythromycin breath testPaul R Hutson
School of Pharmacy, University of Wisconsin, 777 Highland Avenue, Madison, WI 53705, USA
Cancer Chemother Pharmacol 62:373-7. 2008..Medical or surgical castration is a standard treatment of progressive prostate carcinoma, but the effect of the subsequent fall of testosterone concentrations upon drug metabolism has not been reported... - Clinical implementation of adaptive helical tomotherapy: a unique approach to image-guided intensity modulated radiotherapyJames S Welsh
Department of Human Oncology, University of Wisconsin, Madison, Wisconsin, USA
Technol Cancer Res Treat 5:465-79. 2006.... - Rectal dose sparing with a balloon catheter and ultrasound localization in conformal radiation therapy for prostate cancerRakesh R Patel
Department of Radiation Oncology, University of Wisconsin, 600 Highland Avenue K4/B100, Madison, WI 53792, USA
Radiother Oncol 67:285-94. 2003..Such sparing could assist in controlling and limiting rectal toxicity during increasingly aggressive dose escalation... - What hypofractionated protocols should be tested for prostate cancer?Jack F Fowler
Department of Human Oncology, University of Wisconsin Madison, Madison, WI 53792, USA
Int J Radiat Oncol Biol Phys 56:1093-104. 2003..We analyze here possible high-gain/low-risk hypofractionated protocols for prostate cancer to test this suggestion... 
Analysis of urological procedures in men who died from prostate cancer using a population-based approachKara Babaian
Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
BJU Int 111:E65-70. 2013..Furthermore, this study incorporates both hospital- and office-based procedures. This approach has not been previously undertaken...- Management of prostate cancer recurrences after radiation therapy-brachytherapy as a salvage optionGregory W Allen
Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53792, USA
Cancer 110:1405-16. 2007..It appears that salvage brachytherapy, when combined with careful patient selection, is at least as effective as other salvage options with comparable or potentially fewer treatment-related side effects... - Chemoradiation for upper aerodigestive tract cancer: balancing evidence from clinical trials with individual patient recommendationsPaul M Harari
Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, Madison, WI, USA
Curr Probl Cancer 28:7-40. 2004 - Prognostic and predictive markers in radiation therapy: focus on prostate cancerMark A Ritter
Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, USA
Cancer Treat Res 139:97-114. 2008 - Image guidance for precise conformal radiotherapyThomas Rockwell Mackie
Department of Human Oncology, University of Wisconsin, Madison, WI, USA
Int J Radiat Oncol Biol Phys 56:89-105. 2003..Helical tomotherapy has been designed from the ground up as an integrated image-guided intensity-modulated radiotherapy system and allows new verification processes based on megavoltage CT images to be implemented... - Clinical promise tempered by reality in the delivery of combined chemoradiation for common solid tumorsPaul M Harari
Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center and School of Medicine, Madison, WI 53792, USA
Semin Radiat Oncol 13:3-12. 2003..However, we lack randomized trials that directly compare operative versus nonoperative treatment approaches and thus have consciously neglected review of the surgical series for purposes of this article... - Impact of hybrid fluorodeoxyglucose positron-emission tomography/computed tomography on radiotherapy planning in esophageal and non-small-cell lung cancerVinai Gondi
Department of Human Oncology, University of Wisconsin, Madison, WI, USA
Int J Radiat Oncol Biol Phys 67:187-95. 2007..The aim of this study was to investigate the impact of a hybrid fluorodeoxyglucose positron-emission tomography/computed tomography (FDG-PET/CT) scanner in radiotherapy planning for esophageal and non-small-cell lung cancer (NSCLC)... - 3D-ultrasound guided radiation therapy in the post-prostatectomy settingPrakash Chinnaiyan
Department of Human Oncology K4/B100, University of Wisconsin Medical School, 600 Highland Avenue, Madison, WI 53792, USA
Technol Cancer Res Treat 2:455-8. 2003.... - How low is the alpha/beta ratio for prostate cancer? In regard to Wang et al., IJROBP 2003;55:194-203Jack F Fowler
Int J Radiat Oncol Biol Phys 57:593-5; author reply 595-6. 2003 - The prospects for new treatments for prostate cancerJack F Fowler
Int J Radiat Oncol Biol Phys 52:3-5. 2002 - Prostate cancer--which treatment to choose?Jarrod B Adkison
Arch Intern Med 168:1352; author reply 1353. 2008 - Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancersRamesh K Ramanathan
Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
Cancer Chemother Pharmacol 57:465-74. 2006..The pharmacokinetics of MGd were also evaluated... - Platinum-based concurrent chemoradiotherapy for tumors of the head and neck and the esophagusDesiree Hao
Tom Baker Cancer Centre, Alberta Cancer Board and the University of Calgary, Alberta, Canada
Semin Radiat Oncol 16:10-9. 2006..For each tumor type, we will review the state of the evidence and comment on the current state of practice and on future directions for clinical research in combined modality CT/RT... - COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trialLi Yan Khor
Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
Lancet Oncol 8:912-20. 2007..We aimed to study COX-2 overexpression and outcome in a well-defined cohort of men who received treatment with short-term androgen deprivation (STAD) plus radiotherapy or long-term androgen deprivation (LTAD) plus radiotherapy... - Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02Li Yan Khor
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Clin Cancer Res 13:3585-90. 2007..A follow-up investigation was carried out here in more contemporary high-risk men treated on Radiation Therapy Oncology Group 92-02 with STAD+RT or long-term AD+RT (LTAD+RT)...
Research Grants
- Biomarkers of Prostate Cancer Radiation OutcomeMark Ritter; Fiscal Year: 2007..abstract_text> ..
- Hypofractionated IMRT for Localized Prostate CancerMark Ritter; Fiscal Year: 2007..abstract_text> ..